卡维地洛联合凝血酶对肝硬化伴急性上消化道出血患者门静脉血流量、脾静脉血流量及凝血功能的影响OA

Objective To investigate the effect of carvedilol combined with thrombin on portal venous flow(PVF),splenic venous flow(SVF),and coagulation function in patients with liver cirrhosis and acute upper gastrointestinal bleeding(UGIB).Methods A total of 100 patients with liver cirrhosis and acute UGIB admitted to the hospital from January 2022 to January 2025 were selected and divided into the control group and the observation group by the random number table method,with 50 cases in each group.The patients in the two groups were treated with thrombin,while the patients in the observation group were treated additionally with carvedilol.Both groups were treated continuously for 7 d.Results The total effective rate in the observation group was 94.00%,which was significantly higher than 80.00%in the control group(P<0.05).On the third day after treatment,the PVF,SVF,and activated-partial thromboplastin time(APTT)in the observation group were significantly lower than those in the control group(P<0.05).On the seventh day after treatment,the PVF,SVF,APTT,thrombin time(TT),and prothrombin time(PT)in the observation group were significantly lower than those in the control group(P<0.05),while the levels of fibrinogen and cholinesterase in the observation group were significantly higher than those in the control group(P<0.05),and all the above indexes in the observation group were significantly better on the seventh day after treatment than those before treatment(P<0.05).The incidence of adverse reactions in the observation group and the control group was comparable(12.00%vs.8.00%,P>0.05).Conclusion Carvedilol combined with thrombin has a definite clinical efficacy and good safety in the treatment of liver cirrhosis and acute UGIB,which can effectively reduce PVF and SVF,and improve coagulation function.